187 related articles for article (PubMed ID: 33231613)
1. Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists.
Volpe M; Gallo G
Cardiovasc Res; 2021 Jul; 117(9):1992-1994. PubMed ID: 33231613
[No Abstract] [Full Text] [Related]
2. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
Khan MS; Fonarow GC; McGuire DK; Hernandez AF; Vaduganathan M; Rosenstock J; Handelsman Y; Verma S; Anker SD; McMurray JJV; Kosiborod MN; Butler J
Circulation; 2020 Sep; 142(12):1205-1218. PubMed ID: 32955939
[TBL] [Abstract][Full Text] [Related]
3. A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'.
Pabel S; Hamdani N; Sossalla S
Eur J Heart Fail; 2021 May; 23(5):841. PubMed ID: 33377246
[No Abstract] [Full Text] [Related]
4. Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.
Anker SD; Khan MS; Shahid I; Filippatos G; Coats AJS; Butler J
Eur J Heart Fail; 2021 Aug; 23(8):1250-1255. PubMed ID: 34173305
[No Abstract] [Full Text] [Related]
5. Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
Petrie MC; Lee MMY; Docherty KF
Eur J Heart Fail; 2021 Aug; 23(8):1256-1259. PubMed ID: 33502794
[No Abstract] [Full Text] [Related]
6. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
[No Abstract] [Full Text] [Related]
7. Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction.
Berendse J; Newenhouse L
S D Med; 2022 Jul; 75(7):328-329. PubMed ID: 36542574
[No Abstract] [Full Text] [Related]
8. Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?
Patoulias D; Papadopoulos C; Doumas M
Int J Cardiol; 2021 Jan; 323():259. PubMed ID: 32810546
[No Abstract] [Full Text] [Related]
9. Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
Patoulias D; Papadopoulos C; Doumas M
Am Heart J; 2021 Jun; 236():104-105. PubMed ID: 33902820
[No Abstract] [Full Text] [Related]
10. Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.
Butler J; Zannad F; Filippatos G; Anker SD; Packer M
Eur Heart J; 2020 Sep; 41(36):3398-3401. PubMed ID: 32935133
[No Abstract] [Full Text] [Related]
11. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
Berezin AE; Berezin AA
Future Cardiol; 2021 May; 17(3):497-506. PubMed ID: 33615880
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction.
Liang B; Liang Y; Gu N
BMC Cardiovasc Disord; 2022 Jun; 22(1):261. PubMed ID: 35689186
[TBL] [Abstract][Full Text] [Related]
13. The role of cost-effectiveness in the use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.
Liu M; Hao G
Eur J Prev Cardiol; 2023 Jun; 30(8):656-657. PubMed ID: 36740456
[No Abstract] [Full Text] [Related]
14. Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia.
Patoulias D; Papadopoulos C; Fragakis N; Karagiannis A; Doumas M
Am J Cardiol; 2022 Sep; 179():111-114. PubMed ID: 35871863
[No Abstract] [Full Text] [Related]
15. [Serendipity of sodium-glucose co-transporter 2 inhibitors: a new paradigm in the management of heart failure with reduced ejection fraction].
Rosano G; Iacoviello M; Filardi PP
G Ital Cardiol (Rome); 2021 Apr; 22(4):277-283. PubMed ID: 33783447
[TBL] [Abstract][Full Text] [Related]
16. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
[TBL] [Abstract][Full Text] [Related]
18. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango.
Bauersachs J; Soltani S
Eur Heart J; 2023 Oct; 44(37):3697-3699. PubMed ID: 37611060
[No Abstract] [Full Text] [Related]
[Next] [New Search]
